Highlights on Exploring Advances in Headache Medicine from AHS Scottsdale 2024: MaryAnn Mays, MD

WATCH TIME: 5 minutes

“It’s a great time to be in headache medicine as the advances have come out, and you can see the dramatic impact they have on patients, which has been great.”

Headache, including migraine, are among the most prevalent and disabling neurological conditions globally. Migraine, in particular, rank as the second leading cause of disability globally and the top cause among individuals under 50. Characterized by recurrent, debilitating episodes, migraine are often associated with a wide range of comorbidities, underscoring the need for comprehensive approaches to care and treatment.

The American Headache Society's (AHS) Scottsdale 2024 meeting brought together leading experts to discuss advancements in headache medicine. Held at the Camelback Resort for the final time, the event featured engaging precourses and presentations, addressing topics such as migraine as a systemic illness, diversity and inclusion in migraine research, and innovative therapies. Attendees included seasoned professionals, trainees, and advanced practitioners, reflecting the growing scope and interest in the field of headache medicine.

In a recent interview with NeurologyLive^®, an attendee, MaryAnn Mays, MD, neurologist in the Headache Center at Cleveland Clinic, shared her insights into the AHS Scottsdale 2024 meeting, including key themes and emerging research areas. Topics included the growing understanding of migraine as a systemic condition, advancements in CGRP-targeted therapies, and lifestyle-focused approaches to patient care. As the event transitions to a new venue next year, the discussion highlighted the significance of continued innovation and collaboration in headache medicine.